IL1B and congenital rubella syndrome: The administration of anakinra resulted in notable and prompt alleviation of fever, as well as a decrease in inflammatory cytokines and biomarkers linked to ICANS/CRS.528 This treatment has also demonstrated efficacy in patients with CS related to rheumatic conditions.529,530 Similarly, the IL-1β neutralizing antibody canakinumab exhibited anti-inflammatory properties.